Heart Valve Disease Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

The human heart contains four valves — the aortic, mitral, tricuspid, and pulmonary valves — that ensure unidirectional blood flow through the cardiac chambers. Structural or functional abnormalities of any valve produce either stenosis (obstruction to forward flow) or regurgitation (incompetence allowing backward flow), or a combination of both. Valvular heart disease (VHD) affects approximately 2.5% of the general population and rises to 13% in adults over 75 years of age, making it a major burden in ageing populations worldwide.

The 2021 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease (and its 2024 focused update) provides the evidence-based framework for diagnosis and treatment decisions. Central to this framework is a four-stage classification:

• Stage A (At risk): Risk factors present but no valve abnormality or symptoms (e.g., bicuspid aortic valve without stenosis, rheumatic fever history without valve disease).
• Stage B (Progressive): Mild to moderate valve disease with normal haemodynamics; asymptomatic.
• Stage C (Severe asymptomatic): Divided into C1 (severe disease with normal LV/RV function) and C2 (severe disease with LV/RV dysfunction).
• Stage D (Symptomatic severe): The classic triad of heart failure, angina, or syncope in aortic stenosis; dyspnoea, fatigue, or orthopnoea in mitral disease.

Treatment decisions — whether to observe, medically manage, perform percutaneous intervention, or recommend surgery — are determined by the stage of disease, severity on echocardiography, presence of symptoms, left and right ventricular function, and patient risk profile. The Heart Valve Team — comprising a cardiologist, cardiac surgeon, and (increasingly) an interventional cardiologist experienced in transcatheter techniques — is the recommended decision-making body for any patient with significant valvular disease.

Aortic stenosis (AS) is the most common surgically treated valve disease in developed countries. Degenerative (calcific) AS due to progressive calcium deposition on a trileaflet or bicuspid aortic valve is the dominant aetiology in adults over 65. Rheumatic AS from rheumatic fever — the predominant cause in lower-income countries — leads to commissural fusion and leaflet fibrosis. Severe AS is defined echocardiographically by aortic valve area (AVA) ≤1.0 cm², mean transvalvular gradient ≥40 mmHg, and peak jet velocity ≥4.0 m/s. Low-flow, low-gradient AS (LFLG-AS) — characterised by AVA ≤1.0 cm² but gradient <40 mmHg (due to reduced LV function or small LV cavity) — requires dobutamine stress echocardiography or cardiac CT calcium scoring to confirm true severity.

Aortic regurgitation (AR) results from leaflet pathology (bicuspid AV, rheumatic disease, infective endocarditis, degenerative) or aortic root dilation (Marfan syndrome, bicuspid aortopathy, hypertensive dilation). Acute severe AR (from endocarditis or aortic dissection) causes haemodynamic emergency; chronic severe AR produces progressive LV volume overload with compensatory dilation. Surgery is indicated at LVEF <55% or LVESD >50 mm (or >25 mm/m² indexed to BSA) in asymptomatic patients, or at symptom onset.

Mitral stenosis (MS) is predominantly rheumatic in origin (commissural fusion, leaflet thickening, chordal shortening). Mitral valve area (MVA) <1.5 cm² defines severe MS. Significant MS causes elevated left atrial pressure, pulmonary hypertension, right heart failure, and atrial fibrillation. Degenerative calcific MS in the elderly is distinct in mechanism (annular calcium extending to leaflets) and generally less amenable to balloon valvuloplasty.

Mitral regurgitation (MR) is classified by aetiology: primary (degenerative) MR — due to myxomatous degeneration (Barlow's disease), flail leaflet, or mitral valve prolapse; secondary (functional) MR — from LV remodelling in ischaemic or dilated cardiomyopathy displacing the papillary muscles without intrinsic leaflet pathology. Severe primary MR is defined by effective regurgitant orifice area (EROA) ≥0.40 cm² and regurgitant volume ≥60 mL/beat. Severe secondary MR thresholds are lower (EROA ≥0.20 cm²).

Tricuspid regurgitation (TR) is usually secondary (functional) to right ventricular dilation from left-sided heart disease, pulmonary hypertension, or longstanding atrial fibrillation causing annular dilation. Primary TR causes include rheumatic disease, Ebstein anomaly, carcinoid syndrome, and device lead-related TR. Isolated severe TR in the absence of other cardiac disease has traditionally been undertreated; emerging transcatheter tricuspid repair and replacement devices are expanding treatment options.

Pulmonary stenosis (PS) is predominantly congenital; percutaneous balloon valvuloplasty is the treatment of choice for moderate-to-severe congenital PS. Pulmonary regurgitation (PR) is most commonly seen after repair of congenital heart disease (tetralogy of Fallot), leading to progressive RV dilation requiring pulmonary valve replacement (surgical or transcatheter).

Intervention thresholds are defined by the 2021 AHA/ACC guideline and carry Class I, IIa, IIb, or III recommendations based on evidence level (A, B, or C). Key intervention thresholds by valve lesion:

Aortic stenosis (Class I indications for intervention):

• Symptomatic severe AS (Stage D) with symptoms of HF, angina, or syncope — intervention recommended regardless of LVEF.
• Asymptomatic very severe AS (Stage C) with AVA ≤0.6 cm² or mean gradient ≥60 mmHg.
• Asymptomatic severe AS with LVEF <50% (Stage C2).
• Severe AS undergoing other cardiac surgery.

Aortic regurgitation (Class I):

• Symptomatic severe AR (Stage D).
• Asymptomatic severe AR (C2) with LVEF ≤55%.
• Severe AR undergoing other cardiac surgery (CABG, other valve surgery).

Mitral stenosis — percutaneous mitral balloon valvuloplasty (PMBV, Class I):

• Symptomatic severe MS (MVA ≤1.5 cm²) with favourable morphology (Wilkins score ≤8) and no LA thrombus or significant MR.

Primary mitral regurgitation (Class I — surgical):

• Symptomatic severe primary MR (Stage D) with LVEF >30%.
• Asymptomatic severe primary MR (C2) with LVEF ≤60% or LVESD ≥40 mm.
• Severe primary MR undergoing other cardiac surgery.

Secondary mitral regurgitation: Optimal GDMT first; for high surgical risk patients with severe secondary MR who remain symptomatic on GDMT, transcatheter edge-to-edge repair (TEER, MitraClip) has a Class IIa indication (COAPT trial demonstrated mortality benefit in selected anatomy).

Tricuspid regurgitation (Class I): Severe TR in patients undergoing left-sided valve surgery. Isolated symptomatic severe primary TR: surgery Class IIa.

Treatment of valvular heart disease spans a spectrum from medical optimisation to percutaneous intervention to open cardiac surgery. The optimal choice depends on valve lesion, disease stage, patient age, surgical risk, and institutional expertise.

Medical management does not reverse or cure anatomical valve disease but controls symptoms and haemodynamic consequences. Key agents include: loop diuretics (furosemide, torsemide) for congestive symptoms; beta-blockers for heart rate control in atrial fibrillation complicating MS or MR; ACE inhibitors/ARBs for LV afterload reduction and remodelling in chronic AR and secondary MR; anticoagulation (warfarin, target INR 2.0–3.0) for AF complicating MS or as periprocedural bridge; and heart rate-limiting agents (diltiazem, digoxin) for rate control in AF. Medical therapy does not reduce progression of valve disease and should not delay indicated intervention in symptomatic patients.

Percutaneous balloon mitral valvuloplasty (PMBV): The Inoue balloon catheter technique — crossing the interatrial septum via transseptal puncture and inflating a balloon across the mitral valve — splits fused commissures and increases MVA. It is the preferred treatment for symptomatic severe rheumatic MS with favourable anatomy (pliable leaflets, minimal calcification, Wilkins echocardiographic score ≤8, no significant MR). 10-year freedom from re-intervention approaches 60–80% at expert centres. Complications include severe MR from leaflet tear (~2%), stroke from LA thrombus (~1%), and cardiac tamponade from transseptal puncture (<1%).

Transcatheter aortic valve replacement (TAVR): The dominant percutaneous intervention for aortic stenosis; now approved and recommended across all surgical risk categories including low-risk patients. Discussed in detail in the Heart Valve Replacement article.

Transcatheter edge-to-edge repair (TEER): The MitraClip system (Abbott) and PASCAL device (Edwards) clip the anterior and posterior mitral leaflets together, creating a double-orifice valve that reduces MR. TEER is the treatment of choice for high surgical risk patients with severe primary MR (EVEREST II trial) or selected severe secondary MR with anatomy meeting the COAPT trial inclusion criteria (annular diameter ≤70 mm, EROA ≥0.20 cm², LVEF 20–50%, no flail height >10 mm).

Surgical valve repair and replacement: Open cardiac surgery under cardiopulmonary bypass remains the definitive treatment for most valve disease in surgical-risk candidates. Repair is preferred over replacement when feasible. Details of repair and replacement techniques are covered in separate articles.

Treating significant valvular heart disease at the appropriate intervention threshold yields measurable improvements in survival, LV remodelling, symptoms, and quality of life.

Aortic stenosis: The natural history of untreated symptomatic severe AS is grim — median survival after symptom onset is 2 years for HF, 3 years for syncope, and 5 years for angina, with a >50% 2-year mortality without intervention. Aortic valve replacement (surgical or transcatheter) restores near-normal survival: the PARTNER 3 trial demonstrated non-inferior 2-year outcomes (death, stroke, rehospitalisation) for TAVR versus SAVR in low-risk patients, with 5-year data now showing comparable survival. Symptom relief is dramatic — over 90% of patients report significant improvement in dyspnoea and functional class within 1–3 months of intervention.

Mitral regurgitation (primary): Surgical repair of severe primary MR at expert centres achieves excellent long-term outcomes — operative mortality <1% at high-volume centres, with 10-year freedom from reoperation >90% for isolated posterior leaflet prolapse. Timely repair before LVEF falls below 60% or LVESD exceeds 40 mm prevents irreversible LV dysfunction. The STS/ACC TVT registry data show that repair is achievable in >80% of patients undergoing mitral surgery at experienced centres.

Mitral stenosis: Successful PMBV increases MVA from approximately 0.8–1.0 cm² to 1.8–2.2 cm², immediately reducing left atrial pressure and relieving pulmonary oedema. Five-year event-free survival approaches 80% in patients with optimal anatomy.

Tricuspid regurgitation: Concomitant tricuspid repair at the time of left-sided valve surgery significantly reduces the incidence of late progressive TR requiring reintervention (from ~30% to <5% in 5-year follow-up). Isolated severe TR managed conservatively has a poor prognosis, with 5-year survival of 50–60% in symptomatic patients — highlighting the importance of earlier intervention.

The risk profile of treatment depends on the valve affected, the modality chosen (medical, percutaneous, or surgical), patient age, and comorbidity burden. Risk stratification uses the Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) calculator and the EuroSCORE II for surgical procedures.

Surgical valve repair and replacement risks: 30-day operative mortality for isolated aortic valve replacement (AVR) ranges from 1.5–3% in low-risk patients and 5–8% in intermediate-risk; for combined AVR + CABG, mortality is 3–5%. Stroke occurs in 1–3% of cases. Acute kidney injury requiring temporary dialysis affects 3–5%. Permanent pacemaker implantation for complete heart block is required in 2–5% after AVR and up to 8% with extensive annular calcium debridement. Wound infection (including deep sternal wound infection/mediastinitis, 0.5–2%) is the most devastating infectious complication. Blood transfusion in 20–40% of patients.

TAVR-specific risks: Stroke in 2–4% at 30 days; vascular access site complications (bleeding, pseudoaneurysm, AV fistula) in 2–5% with transfemoral access; paravalvular leak (mild PVL in 20–40%, moderate-severe in 5–10%, associated with worse outcomes); new permanent pacemaker for LBBB or complete heart block in 10–20% (higher with self-expanding valves); coronary obstruction (rare, <1%, treated with coronary protection via BASILICA technique); and prosthesis-patient mismatch if undersized.

TEER (MitraClip) risks: Clip embolisation or detachment (<1%); single leaflet device attachment (<1%); need for conversion to open surgery (<1% in experienced centres); residual MR; and MV stenosis if orifice area is overly reduced after clipping (<1.5 cm² in some cases).

Infective endocarditis (IE): Prosthetic valve endocarditis — affecting 0.3–0.6% of prostheses per year — is a devastating complication with 20–40% in-hospital mortality. AHA/ACC guidelines recommend IE prophylaxis (amoxicillin 2 g single dose prior to dental procedures) for patients with prosthetic valves, prior IE, unrepaired cyanotic congenital heart disease, or certain repaired congenital defects within 6 months.

Patients with known or suspected valvular heart disease require structured longitudinal follow-up, with the intensity of monitoring guided by valve lesion severity, intervention status, and individual risk factors.

Echocardiographic surveillance intervals (per 2021 AHA/ACC guidelines):

• Mild-to-moderate AS (Stage B): TTE every 3–5 years for mild, every 1–2 years for moderate AS.
• Severe asymptomatic AS (Stage C): TTE every 6–12 months; exercise stress testing to unmask symptoms is reasonable in patients claiming to be asymptomatic.
• Mild-to-moderate AR (Stage B): TTE every 3–5 years for mild, every 1–2 years for moderate; annual for severe asymptomatic AR with LVEF ≥55%.
• Primary MR Stage B: TTE every 3–5 years; Stage C1 (severe asymptomatic): every 6–12 months.
• Mild-to-moderate MS: TTE every 3–5 years; severe MS not yet treated: every 6–12 months.

Post-procedure surveillance: After surgical valve repair or replacement, baseline TTE at 30 days (or pre-discharge), then at 6–12 months, and annually thereafter to detect structural valve deterioration (SVD), paravalvular regurgitation, prosthetic valve dysfunction, or incomplete repair. After TAVR, TTE is recommended at 30 days and 1 year. After TEER (MitraClip), TTE at 30 days, 6 months, and 1 year.

Anticoagulation monitoring: Patients with mechanical prostheses require lifelong warfarin with INR monitoring every 4 weeks when stable (monthly INR testing); INR target is 2.0–3.0 for aortic mechanical valves and 2.5–3.5 for mitral mechanical valves (higher thrombogenicity). ON-X aortic mechanical valve recipients may be maintained at INR 1.5–2.0 after the first 3 months per prospective trial data (PROACT trial). Direct oral anticoagulants (DOACs) are contraindicated for mechanical prostheses (RE-ALIGN trial demonstrated harm with dabigatran).

The cost of valvular heart disease treatment varies widely by modality and geography.

Echocardiography and diagnosis: Transthoracic echocardiography (TTE) costs USD 800–2,500 in the US; transesophageal echocardiography (TEE) USD 2,000–5,000. Cardiac CT for calcium scoring or TAVR planning — USD 1,000–3,000. In India, TTE at private hospitals ranges from USD 30–100; in the UK via NHS, no direct patient cost.

Percutaneous balloon mitral valvuloplasty (PMBV): USD 8,000–20,000 in the US; USD 2,000–5,000 in India (making India a significant destination for medical tourists with rheumatic MS).

Transcatheter aortic valve replacement (TAVR): The Edwards SAPIEN 3 and Medtronic Evolut Pro+ devices cost USD 28,000–35,000 for the device alone; total procedural cost (device + hospital + physician) ranges from USD 50,000–100,000 in the US. TAVR is significantly less costly outside the US — approximately USD 15,000–25,000 in Germany, USD 18,000–30,000 in Singapore, and USD 12,000–20,000 in India at accredited centres.

Surgical valve surgery (open): Isolated surgical aortic valve replacement (SAVR) — USD 80,000–150,000 in the US including hospitalisation; USD 6,000–18,000 in India; USD 15,000–35,000 in Thailand. Mitral valve repair — USD 100,000–180,000 in the US; USD 7,000–20,000 in India. Combined procedures (AVR + CABG or double valve surgery) add 30–50% to costs. Most developed countries cover these costs via national health insurance or public funding, with waiting times the primary limiting factor.

Medical tourism for cardiac valve surgery is well-established, with accredited programmes in India (Apollo, Fortis, Narayana Health), Thailand (Bumrungrad, Samitivej), Singapore (National Heart Centre, Mount Elizabeth), and Turkey (Acibadem, Memorial). Joint Commission International (JCI) accreditation is a marker of international quality standards.

Not all patients with valvular heart disease require immediate intervention. The decision to observe versus intervene is nuanced and must balance procedural risk against the natural history of untreated disease.

Watchful waiting (medical observation): Asymptomatic patients with mild to moderate valve disease (Stage A–B), or severe disease with preserved LV function and no symptoms, can be safely monitored with structured echocardiographic surveillance. Key is distinguishing truly asymptomatic status from denial or limitation of activity — formal exercise stress testing reveals symptoms in approximately 30–40% of patients claiming to be asymptomatic with severe AS. Once symptoms develop, intervention should not be delayed.

Medical optimisation before intervention: In patients with secondary MR or functional TR, optimising GDMT (including CRT if indicated, SGLT2 inhibitors, sacubitril/valsartan) can reduce MR/TR severity through LV/RV reverse remodelling, potentially deferring or avoiding intervention. In HFrEF patients with new severe secondary MR, a 3–6 month trial of GDMT is recommended before reassessing TEER candidacy.

Balloon aortic valvuloplasty (BAV): Percutaneous balloon dilation of the calcific aortic valve provides temporary haemodynamic improvement but restenosis occurs in 6–12 months in nearly all patients. BAV is not a definitive therapy but is used as a bridge to TAVR or SAVR in haemodynamically unstable patients, or as a diagnostic tool to assess symptomatic response before committing to valve replacement in patients with multiple comorbidities.

Transcatheter tricuspid therapies: The rapidly evolving field of transcatheter tricuspid interventions offers alternatives to open surgery for high-risk patients with isolated severe TR. Devices include the TriClip (edge-to-edge repair, Abbott), CLASP TR (Edwards), PASCAL CLASPER (Edwards), Cardioband TC (Edwards annuloplasty system), and EVOQUE transcatheter tricuspid replacement (Edwards). Registry data show high procedural success and meaningful TR reduction, with mortality benefit data emerging from the TRILUMINATE Pivotal trial.